Healthcare Triangle, Inc. — Q3 2021 Form 10-Q
Business context and reporting period. The company provides IT, cloud, data, and consulting services to healthcare and life sciences organizations. This unaudited quarterly report covers the three and nine months ended September 30, 2021, with comparisons to the same periods in 2020. Its reportable segments are Software Services, Managed Services and Support, and Platform Services.
Financial performance and liquidity
- Revenue: Q3 revenue was $8.08 million, up 10% year over year. Nine-month revenue was $26.08 million, up 17%.
- Profitability: Q3 net loss was $1.99 million versus net income of $138,809 a year earlier; nine-month net loss was $2.50 million versus net income of $476,983. Basic and diluted loss per share were $0.069 for Q3 and $0.087 for the nine-month period.
- Margins: Gross margin, calculated as revenue less cost of revenue before depreciation and amortization, was approximately 33.7% in Q3 versus 27.2% in Q3 2020, and 31.6% for the first nine months versus 27.7% in 2020. Operating losses were $1.77 million for Q3 and $2.02 million for the nine-month period.
- Segment trends: Q3 Managed Services and Support revenue rose 18% to $4.67 million; Platform Services rose 33% to $1.10 million; Software Services fell 10% to $2.31 million. For the first nine months, the respective changes were +38%, +57%, and -15%. Platform Services reported operating losses of $1.55 million in Q3 and $1.64 million for nine months.
- Cash flow: Nine-month operating cash use was $3.88 million, investing cash use was $50,354, and financing cash inflow was $3.67 million. Cash declined $254,271 from year-end 2020 to $1.15 million.
- Balance sheet and debt: At September 30, cash was $1.15 million, accounts receivable $5.91 million, unbilled revenue $763,601, and current liabilities $8.68 million. Current liabilities included $1.95 million of convertible notes, $2.35 million of warrant liability, and a $1.07 million PPP loan. The company reported $2.71 million of stockholders’ equity and no long-term liabilities.
- Liquidity: Current assets were $8.51 million, implying a current ratio of approximately 0.98. Management stated it expected available funds and future operating cash flows to meet requirements for at least 12 months, but cautioned that additional funding might be needed if cash generation or financing proved insufficient.
Material changes versus the prior comparable period
- Revenue growth was led by Managed Services and Support and Platform Services, while Software Services declined. Management attributed Software Services weakness partly to delayed deals, customer cost optimization, and pandemic-related travel restrictions.
- Research and development expense increased 301% to $2.20 million in Q3 and 157% to $3.77 million for nine months, primarily due to platform development. Sales and marketing expense rose 179% in Q3 and 154% for nine months as the company invested in growth.
- Interest expense rose to $220,634 in Q3 and $479,849 for nine months, primarily reflecting convertible-note interest. Unallocated costs increased 99% in Q3 and 91% for nine months, contributing to operating losses despite segment-level revenue growth.
- Customer concentration remained substantial: the five largest customers represented 79% of Q3 revenue and approximately 75% of nine-month revenue. One customer accounted for $11.30 million, or about 43%–44%, of nine-month revenue, depending on the filing disclosure.
Outlook, risks, and unusual items
- Management expects to continue investing in research and development, sales and marketing, and administrative capacity. It expects these investments to increase in absolute dollars.
- CloudEz, DataEz, and Readabl.AI were being marketed toward subscription offerings, which management expected to become commercially available in Q1 2022. The filing says customer acceptance and the potential revenue impact were not yet clear; it provides no quantified revenue or earnings guidance.
- Management reported no major COVID-19 impact during Q3 2021, while noting continuing pandemic-related uncertainty and earlier disruption to certain healthcare projects and travel-dependent services.
- Convertible notes carried a 10% annual interest rate and included conversion and default provisions. The filing reported a $2.35 million warrant liability measured at fair value, with valuation sensitive to stock price, volatility, and other assumptions.
- Subsequent event: After quarter-end, the company completed an IPO, issuing 3,262,500 shares at $4 per share for $13.05 million gross and $11.80 million net proceeds; trading began on Nasdaq on October 13, 2021. It also repaid $381,188 of convertible-note obligations and converted the stated remaining $4.06 million into 1,693,492 shares at $2.40 per share.
- The company said it had received notice that its PPP loan would be forgiven. It reported no material legal proceedings and no material changes to risk factors disclosed in its IPO prospectus. Management concluded disclosure controls were effective as of September 30, 2021.
Important facts for investors to verify
- Reconcile the MD&A’s stated current ratio of 1.98 with the balance-sheet figures, which calculate to approximately 0.98.
- Confirm the post-IPO repayment and conversion of convertible notes, including the remaining principal, accrued interest, share issuance, and the treatment of the warrant liability.
- Check customer concentration disclosures: the largest customer is reported as 43% in one table and 44% elsewhere for the nine-month period.
- Assess the sustainability and cash requirements of the company’s growth investments, platform segment losses, and management’s 12-month liquidity expectation.
- Note that the filing’s cover page marks “No” for having filed all required reports during the preceding 12 months; verify the reporting history and any implications.